RxDoctor Payments Data

Roberto Salcedo, MD

Neurology · Hermitage, PANPI 1417930959

Payments from drug & device makers

$84,485in general payments, 2019–2025

Across 1,416 payments — averaging $59.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$55K
  • Catalyst Pharmaceuticals, Inc.$4K
  • Biogen$2K
  • UCB, Inc.$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Genentech USA, Inc.$1K
  • plus $17K from 49 others

What the payments were for

  • Consulting fees$5,5427%
  • Speaking & faculty fees$48,66758%
  • Travel & lodging$1,0631%
  • Food & beverage$29,02434%
  • Education$1900%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$84,485 in reported general payments places this provider in the 85th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$126,670
Medicare patients
325
Services billed
2,014

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TecfideraDimethyl Fumarate13$114,503
VumerityDiroximel Fumarate12$105,668
Aimovig AutoinjectorErenumab-Aooe76$55,915
NuedextaDextromethorphan Hbr/Quinidine31$54,105
BriviactBrivaracetam14$44,493
Emgality PenGalcanezumab-Gnlm36$29,610
DepakoteDivalproex Sodium27$21,215
Lacosamide127$15,827
Ajovy AutoinjectorFremanezumab-Vfrm16$11,449
Levetiracetam317$10,979
Carbamazepine111$10,179
Pramipexole ErPramipexole Di-Hcl11$9,779
Carbidopa-LevodopaCarbidopa/Levodopa392$9,518
Memantine Hcl316$8,294
DilantinPhenytoin Sodium Extended40$7,654

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera, Vumerity$2,420$220,17125 claims
Avanir Pharmaceuticals, Inc.Nuedexta$77$54,10531 claims
UCB, Inc.Briviact$2,401$44,49314 claims
PfizerDilantin, Eliquis$525$14,31052 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$317$2,04927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Hermitage

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →